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Abstract
Trypanosoma evansi infections (including Surra) have been assessed according to the criteria of the
Animal Health Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on
the eligibility of T. evansi infections (including Surra) to be listed, Article 9 for the categorisation of
T. evansi infections (including Surra) according to disease prevention and control rules as in Annex IV
and Article 8 on the list of animal species related to T. evansi infections (including Surra). The
assessment has been performed following a methodology composed of information collection and
compilation, expert judgement on each criterion at individual and, if no consensus was reached before,
also at collective level. The output is composed of the categorical answer, and for the questions where
no consensus was reached, the different supporting views are reported. Details on the methodology
used for this assessment are explained in a separate opinion. According to the assessment performed,
it is inconclusive whether T. evansi infections (including Surra) can be considered eligible to be listed
for Union intervention as laid down in Article 5(3) of the AHL because there was no full consensus on
the criterion 5 A(v). Consequently, the assessment on compliance of T. evansi infections (including
Surra) with the criteria as in sections 4 and 5 of Annex IV of the AHL, for the application of the disease
prevention and control rules referred to in points (d) and (e) of Article 9(1) is also inconclusive, as well
as which animal species can be considered to be listed for T. evansi infections (including Surra)
according to Article 8(3) of the AHL.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL)
framework (EFSA AHAW Panel, 2017).
The present document reports the results of assessment on Trypanosoma evansi infections
(including Surra) according to the criteria of the AHL articles as follows:
• Article 7: Trypanosoma evansi infections (including Surra) proﬁle and impacts.
• Article 5: eligibility of Trypanosoma evansi infections (including Surra) to be listed.
• Article 9: categorisation of Trypanosoma evansi infections (including Surra) according to
disease prevention and control rules as in Annex IV.
• Article 8: list of animal species related to Trypanosoma evansi infections (including Surra).
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of T. evansi infections (including Surra) according to the
Article 7 criteria of the AHL and related parameters (see Table 2 of the opinion on methodology (EFSA
AHAW Panel, 2017)), based on the information contained in the fact-sheet as drafted by the selected
disease scientist (see section 2.1 of the scientiﬁc opinion on the ad hoc methodology) and amended by
the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Trypanosoma (Trypanozoon) evansi (Steel 1885) Balbiani, 1888, was the ﬁrst pathogenic
mammalian trypanosome to be described in the world, in 1880, by Grifﬁth Evans, in the blood of
Indian equines and dromedaries (Hoare, 1972). T. evansi is a parasite derived from the
Trypanosoma brucei lineage; compared to T. brucei subsp., it is genetically characterised by a loss of
kinetoplastic maxicircles (which makes it unable to develop in tsetse ﬂies) and a high homogeneity in
the kinetoplastic minicircles (Lun and Desser, 1995). Surra is the disease caused by T. evansi infections
which may occur in a large range of mammals (Hoare, 1972), and very occasionally in humans (Truc
et al., 2014). T. evansi is mainly mechanically transmitted by biting insects such as tabanids and
stomoxys. Therefore, the disease is able to spread outside the tsetse distribution area in Africa,
towards the Middle East and Asia but also to Latin America.
Surra is an acute, chronic or subclinical disease being very often fatal in camels, horses and dogs,
but can also seriously affect cattle and buffaloes. It is generally a mild disease in goats, sheep and
pigs. Surra is also known as Mal de caderas, Peste-Boba or Derrengadera in Latin America and El
debab, Mbori, Guifar and Menchaca in Africa (Desquesnes et al., 2013b). Surra can cause fever,
anaemia, weakness and nervous symptoms; it is responsible for major production losses (meat, milk,
draught power, manure and fertility), leading to cachexia and sometimes abortion and/or death in the
absence of treatment (Desquesnes et al., 2013b).
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3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Almost all wild mammals are known to be susceptible to T. evansi infection:
• Perissodactyla: Tapiridae (Hoare, 1972) and Rhinoceritidae (Mohamad et al., 2004);
• Artiodactyla, notably antelopes, Cervidae (sambar deer (Rusa unicolor), Rusa deer
(Rusa timorensis) (Indrakamhang, 1998), hog deer (Axis porcinus) (Tuntasuvan et al., 2000),
barking deer (Muntiacus muntjak) and spotted deer (Axis axis) (Losos, 1980), Suidae (wild
pigs) and Tayassuidae (Herrera et al., 2008);
• Carnivora: coati (Nasua nasua) (Silva et al., 1996), wild dogs, foxes (Hoare, 1972), tiger
(Panthera tigris) (Bhaskararao et al., 1995), ocelot (Leopardus pardalis) (Herrera et al., 2011),
Asiatic black bear (Ursus thibetanus) (Muhammad et al., 2007), leopards (Panthera pardus)
and jaguars (Panthera onca) (Sinha et al., 1971);
• Proboscidea: Asian elephant (Elephas maximus) (Evans, 1910);
• Rodentia: capybara (Hydrochoerus hydrochaeris) (Reveron et al., 1992), common hamster
(Cricetus cricetus) (Stephen, 1986) and rats (Arias et al., 1997; Milocco et al., 2013);
• Lagomorpha: pika (Ochotona spp.) (Hoare, 1972);
• Chiroptera: vampire bats (Hoare, 1965);
• Primates: orangutan (Pongo pygmaeus; Pongo abelii), howler-monkey (Alouatta sp.) (Van den
Berghe, 1939; Ruiz-Martinez, 1971).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
Almost all domestic mammals are known to be susceptible to infection with T. evansi:
• Perissodactyla, notably Equidae (horse, donkey and their crossbreeds) (Hoare, 1972);
• Artiodactyla, notably Camelidae (Bactrian and dromedary camels but also llamas (Ferris, 1984;
Gardiner and Mahmoud, 1992), Bovidae (cattle, sheep, goats, Asian buffalo) and Suidae (pig)
(Hoare, 1972; Gill, 1977);
• Carnivora (dog, cat) (Tarello, 2005);
• Proboscidea: Asian elephant (Evans, 1910).
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
The following species were experimentally infected: wallabies (Reid et al., 2001), mongooses (Misra
et al., 2016), Proechimys sp. (Morales and Carreno, 1976) and Macaca mulatta (Vittoz, 1955; Misra
et al., 2016). Experimental infection of young pigeons was obtained (Mandal et al., 2008).
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Rabbits (Uche and Jones, 1992), guinea pigs, rats, mice, guanacos (Lama guanicoe) (Kinne et al.,
2001), goats (Morales et al., 2006), cats and dogs (Moloo et al., 1973; Misra et al., 2016).
Parameter 5 – Wild reservoir species (or family/orders)
Deer, wild pigs, capybaras (Morales et al., 1976; Rodrigues et al., 2009) and vampire bats (Hoare,
1965, 1972).
Parameter 6 – Domestic reservoir species (or family/orders)
Natural domestic reservoirs of T. evansi are varied according to the geographical areas; in Africa,
they appear to be camels themselves (Hoare, 1972), in Latin America and Asia, cattle and buffaloes
are the main reservoir (Hoare, 1965; Desquesnes, 2004; Desquesnes et al., 2013a,b). Other occasional
reservoirs are domestic deer and donkeys. Overall, camels, cattle and buffaloes remain the main
domestic reservoir of T. evansi, but goats and sheep may also play a role (Boehringer and Prosen,
1961; Birhanu et al., 2015).
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3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
The prevalence and incidence depend on the host species and the vector activity. In horses, at
population level, the prevalence is generally very low (Berlin et al., 2012), but at the farm level, the
incidence can be very high within a short period of time during biting-insects season (Laha and
Sasmal, 2009); however, in some highly enzootic areas in India and Latin America, prevalence can be
high (Silva et al., 1995b; Jaiswal et al., 2015; Da Silva et al., 2016). In camels, prevalence might reach
20–70% (OIE, online). In buffaloes and cattle, the prevalence and incidence are generally low (around
10%) (Desquesnes et al., 2009b; Kocher et al., 2015a) but can be high in some outbreaks with strong
clinical signs (Chartier et al., 2000). Domestic dogs present low prevalence due to sporadic infections
most often linked with ingestion of infected meat (Singh et al., 1993; Hosseininejad et al., 2007;
Ravindran et al., 2008).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
The case-morbidity rate is always very high in horses and dogs (> 90%) (Singh et al., 1993; Silva
et al., 1995b).
It is high in camels, > 40% (Tehseen et al., 2015).
It is medium to low in other hosts, such as cattle, sheep and goats (Losos, 1980; FAO, 1998);
Jaiswal et al., 2015).
Mortality
Parameter 3 – Case-fatality rate
The case-fatality rate is always very high in horses and dogs (> 90%) (Eloy and Lucheis, 2009).
It is high to medium in camels and elephants, sometimes high in buffaloes and cattle (in na€ıve
populations) (Reid, 2002).
It is medium to low in deer, buffaloes and cattle in enzootic areas (Reid, 2002; Desquesnes et al.,
2013b).
The case-fatality rate is generally low in pigs, sheep and goats (Boehringer and Prosen, 1961;
Losos, 1980). Figures of clinically sick animals can be seen in Desquesnes et al. (2013a).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases worldwide
Apart from the cases observed in Africa, for which the Trypanosoma species was not conﬁrmed, six
human cases have been reported so far in Asia, among them two recent cases fully documented
(including molecular identiﬁcation, treatment and clinical and laboratory follow-up of the patient until
full recovery); one in India linked with a deﬁcit in apolipoprotein-L1 (ApoL1), another one in Vietnam;
in both cases, transcutaneous infection was suspected (Joshi et al., 2005; Powar et al., 2006;
Shegokar et al., 2006; Vanhollebeke et al., 2006; Van Vinh Chau et al., 2016). The case in Vietnam
could have been due to transient deﬁciency in ApoL1 in the blood as a result of liver dysfunction.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
Trypanosomes have developed chemoresistance in most parts of the world (Peregrine and
Mamman, 1993). Individual resistance of some strains of T. evansi to trypanocides has been recorded,
notably in China and Sudan, but there is no report of natural cross-resistance to all trypanocides
available (Zhang et al., 1991; El Rayah et al., 1999). Despite this, it appears that there is no drug
available which can cure the disease once the nervous system of the host is invaded (Tuntasuvan
et al., 1997, 1998, 2000).
AHL assessment on Trypanosoma evansi infections (including Surra)
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3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
In horses, evolution is generally fast, but chronic cases can occur for 3 months to 3 years or more
(Gill, 1977), whereas in camels evolution is generally fast, although chronic cases can occur for more
than 3 years (Rottcher et al., 1987). Also, in dogs, the evolution is fast and fatal, usually within
2 months (Gill, 1977; Herrera et al., 2004; Rjeibi et al., 2015).
In bovines, persistence of the disease is generally of medium term (3 months), but persistence of
the infection may last several months or years (OIE, 2012), while in capybaras, vampire bats and
some other wild host species, the duration of the infectious period is not limited in time (Hoare, 1965).
In wild rodents, it is not known whether the parasite can persist for long periods, but survival of
infected animals may last one month or more (Kocher et al., 2015b).
Parameter 2 – Presence and duration of latent infection period
The period between infection and the appearance of clinical signs has been estimated as 5–30 days
in horses and dogs, 5–60 days in camels, but it can be as high as 4 months and possibly inﬁnite in
bovines and some other hosts of mild susceptibility (Hoare, 1972). The period from infection to
possible detection using laboratory tests has been arbitrarily deﬁned as 6 months in cattle, camel and
horse by the ad hoc group of the OIE on Surra.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
T. evansi can remain in the host for several months or even years and relapse in bovines and
camels (Mohler and Thompson, 1909; Hoare, 1972; Rottcher et al., 1987; OIE, 2012).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
There is no survival in the environment; survival in meat is considered to be below 2 days, based
on expert’s opinion, and length of survival in the blood at 4°C, declines dramatically after 48 h, even if
living parasites can still be found 7 days after blood collection (Monzon et al., 1995a).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
In herbivores, the main route of transmission is through haematophagous ﬂies acting as mechanical
vectors (horizontal transmission); transmission can thus be fast, but is seasonal, and requires close
proximity between animals. The main vectors are biting haematophagous ﬂies (Diptera) included in the
family Tabanidae (Horseﬂies, deer ﬂies and clegs are the main vectors); other species included in
different families, such as Stomoxys spp., Haematobia spp. and some non-biting haematophagous ﬂies
are also suspected, such as Musca crassirostris (Gill, 1977; Desquesnes et al., 2013b).
Vertical transmission can occur especially in bovines, sheep and donkeys and possibly in camels,
but is of low prevalence; it may not occur in horses and dogs due to the severity of the clinical signs
leading to abortion and death (Pathak and Kapoor, 1999; Campigotto et al., 2015; Kumar et al., 2015).
Horizontal transmission via colostrum and milk has been described in experimental infections of
sheep (Campigotto et al., 2015). Transmission of T. evansi to carnivores generally occurs via the
peroral route, from infected herbivore meat (dogs/slaughter houses) or wildlife (for wild carnivores or
hunting dogs) (Desquesnes, 2004). Vampire bats can get the infection perorally (through the stomach
mucosae) when biting and sucking blood on infected herbivores, or other bats of the colony, or by
transcutaneous route when being bitten by infected congeners (in Latin America only) (Hoare, 1965).
AHL assessment on Trypanosoma evansi infections (including Surra)
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Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
The rare cases of infections of humans by T. evansi have been reported to be either accidental
inoculation (iatrogenic) or contamination by infected meat or blood through a skin wound (Joshi et al.,
2005, 2006; Powar et al., 2006; Shegokar et al., 2006; Van Vinh Chau et al., 2016); however, some
other routes might be efﬁcient such as peroral infection (Vergne et al., 2011) and mechanical
transmission by arthropods (tabanids and stomoxys) (Desquesnes et al., 2013a).
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
The incidence might be very high (up to 100%) in highly susceptible herbivores (horses and
camels) when they exhibit high parasitaemia in the presence of high densities of mechanical vectors.
The incidence is moderate in bovines because of moderate susceptibility to infection and moderate
risk of disease development (Dia and Desquesnes, 2007).
The incidence is sporadic in carnivores while the peroral route of infection requires feeding on
infected carcasses (Jaiswal et al., 2015).
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
No data are available on the transmission rate of Surra. However, one model has been developed
so far on Surra in buffaloes in the Philippines, where infection rates (success) for Surra were set
differently for innate susceptible (S to I) and innate resistant (R to I) hosts, that is, 0.2 for innate
resistant animals and 0.8 for innate susceptible hosts. The values used were estimated from ﬁeld data
(Dobson et al., 2009).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
The disease is absent from the continental European Union at the present time as shown in Figure 1;
however, T. evansi is present (endemically in the wild fauna) in French Guiana (Desquesnes, 2004) and
in the Canary Islands (endemic/epidemic in camels) (Molina et al., 1999; Gutierrez et al., 2000).
Figure 1: Distribution of the Trypanosoma disease in the world (Desquesnes et al., 2013a)
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Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
Sporadic outbreaks occur, most recently from camels imported from the Canary Islands, in Aveyron,
France, in 2005 (Desquesnes et al., 2007, 2008) and in Alicante, Spain, in 2008 (Tamarit et al., 2010).
Recent outbreaks in camels or camels and horses were observed respectively in France and Spain
(Gutierrez et al., 2010).
In French Guiana, T. evansi is rarely but regularly observed only in hunting dogs because Surra is
thought to be endemic in wildlife only (Desquesnes, 2004).
Surra has been demonstrated in camels in the Canary Islands (Gutierrez et al., 2000) with an
epidemic nature (Gutierrez et al., 2005).
Risk of introduction
As surra is present in the French Guyana and in the Canary Islands, the following points are
addressed only considering the risk of introduction into the continental EU.
Parameter 3 – Routes of possible introduction
Both controlled and uncontrolled movements of wild and domestic large herbivores should be
considered as possible route of introduction of surra from Turkey into the continental EU (Azrug and
Burgu, 2011). Large herbivores as healthy carriers or incubating animals are the main potential source
of introduction; they could be mostly camels, horses or bovines, and possibly sheep, goats and pigs;
so far, the two cases observed in Spain and France were due to importation of camels (Gutierrez et al.,
2010). Also controlled and uncontrolled movements of dogs, hamster, pikas and lagomorphs could act
as possible route of introduction.
Parameter 4 – Number of animal moving and/or shipment size
Data on uncontrolled wild and domestic animals entering EU from Turkey are not known. The
number of camels introduced into EU has been so far very limited (< 20 per MS/year).
Parameter 5 – Duration of infectious period in animal and/or commodity
See Section 3.1.1.5.
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
Import of bovines, sheep, goats and pigs are only allowed into the European Union (EU) if the
animals originate from authorised third countries: Andorra, Chile, Canada, Greenland, Island, Mayotte,
New Zealand and Saint Pierre et Miquelon. These countries are not enzootic countries for surra; the
certiﬁcate does not include any testing for surra, which might not be fully safe as concerns Chile, due
to close vicinity with infected areas (Peru, Bolivia and Argentina).
For camelids originating from non-authorised countries, a quarantine should be made in Saint Pierre
et Miquelon, documents for ‘Rum’ and ‘Cam’ should be exhibited as well as a negative blood smear
examination at 2 and 42 days after their arrival (Annex I to Regulation (EC) No 206/20101); since this
diagnostic method is of very low sensitivity, the risk of undetected carrier is signiﬁcant.
For live Equidae and their products, temporary or permanent importations are strictly regulated for
each type and third country according to a Commission Decision of 6 January 2004 (2004/211/EC).2
However, in this list at least six countries are authorised to export all types of equines to the EU,
although they are known to be enzootic for Surra; namely: Argentina (Monzon and Colman, 1988;
Monzon et al., 1995b, 2003; Bono Battistoni et al., 2016), Algeria (Bennoune et al., 2013), Morocco
(Atarhouch et al., 2003), Tunisia (Hoare, 1972; Rjeibi et al., 2015), Israel (Berlin et al., 2012) and
Paraguay (Hoare, 1972).
Due to latent infections, carrier status and possible presence of viable parasites in the semen or
other biological products, animals, or products of animal origin, should be born in or originated from
authorized country, bred in surra-free farms, be submitted to quarantine and pass successfully at least
3 laboratory tests including blood examination, serological (ELISA & CATT) and molecular detection
1 Regulation (EC) No 206/2010 of the European Parliament and of the Council of 12 March 2010 laying down lists of third
countries, territories or parts thereof authorised for the introduction into the European Union of certain animals and fresh meat
and the veterinary certiﬁcation requirements (1). OJ L 73, 20.3.2010, p. 1–121.
2 Commission Decision of 6 January 2004 establishing the list of third countries and parts of territory thereof from which Member
States authorise imports of live equidae and semen, ova and embryos of the equine species, and amending Decisions 93/195/
EEC and 94/63/EC (2004/211/EC). OJ L 73, 11.3.2004, p. 1.
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(PCR) as described in surra chapter of the OIE terrestrial manual (Chapter 2.1.17) (OIE, 2012). Such
measures should be elaborated carefully to avoid the risk of introduction.
Parameter 7 – Presence and duration of latent infection and/or carrier status
Latent infection and/or carrier status can occur and last for several months to years in camels and
bovines and possibly in small ruminants. Serological detection might not always be able to detect such
animals when they are in the incubation period (Desquesnes et al., 2008, 2009a).
Parameter 8 – Risk of introduction
Large herbivores as healthy carriers or incubating animals can introduce viable parasite into EU.
Lesson learn from the previous camel introductions onto the French and Spain mainlands, trading of
camels from infected area should be made with extreme precautions. Providing reliable laboratory
examinations be carried out (e.g. by one of the 3 OIE reference laboratories) and the limited amount
of imported animals, such risk, could still be considered as very unlikely.
For horses that fall in the category of ‘high health, high performance’ (HHP) as deﬁned by the OIE,
regulations are less strict since the health status of this equine subpopulation is safeguarded by the
application of speciﬁc measures pertaining to veterinary supervision and certiﬁcation, identiﬁcation,
traceability and compliance to biosecurity measures. This is aimed to create and maintain a functional
separation between these horses and other equids, at all times, including the usual place of residence
and venues of international competitions, and during transport by road or air. As far as this compliance
is assured and validated through continuous veterinary supervision, for these animals, risk can be
considered as very unlikely.
Import testing of animals for Surra should be carried out in countries such as Greece and Bulgaria,
since they might be opportunity to introduce the parasite into Europe from the bordering Turkey
(Azrug and Burgu, 2011). Concerning uncontrolled movement of animals, considering that it is very
difﬁcult to provide a reliable estimation and that transboundary movements of wild animals cannot be
easily controlled, such risk of introduction cannot be estimated.
Dogs might be carriers for a short time before they exhibit clinical signs, however they are not an
efﬁcient source of infection to spread the disease; they are rather epidemiological dead-end hosts
(Desquesnes et al., 2013a). Hamsters and pikas have been found naturally infected (Kazakhstan) and
could be a way of introduction if transported and not checked at borders, however, they would hardly
act as a source to infect large mammals (Hoare, 1972). Lagomorphs have been proved to be
experimentally susceptible hosts to T. evansi infections and their movement could act as route of
possible introduction, however, they have not been found naturally infected (Uche and Jones, 1992;
Da Silva et al., 2011; Misra et al., 2016), thus the risk of introduction can be considered negligible.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Several diagnostic tools are available; those recommended by the OIE (terrestrial manual, chapter
2.1.17) are the following (OIE, 2012):
• Giemsa stained blood smear microscopic examination;
• Fresh blood examination with a microscope can be proceeded, either with plain blood or better
after centrifugation in a capillary tube (haematocrit centrifuge technique (HCT)) (Woo, 1970);
• PCR methods can be applied to plain blood or more sensitive with buffy coat, using primers of
various taxon levels from subgenus Trypanozoon (Masiga et al., 1992), species (Panyim et al.,
1993), to type A Rotat 1.2 (Claes et al., 2004) or type B T. evansi (Njiru et al., 2006);
• Card agglutination test (CATT) for T. evansi is commercially available from ITM Anvers, Belgium
for antibodies detection direct agglutination test;
• ELISA T. evansi for immunoglobulin G (IgG) detection is described in the OIE terrestrial book,
only referenced laboratories can prepare the antigens made of the soluble proteins from a
whole cell lysate of T. evansi.
A trypanolysis test (TT) is also available at the OIE reference laboratory of ITM, Anvers, Belgium.
This test is more speciﬁc and is mainly applied as serological conﬁrmation of CATT or ELISA
seropositive animals. The major disadvantages of this test are the use of living animals, the high cost
(around 250 €) and the fact that it will not detect infections with T. evansi type B, the rare type of
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T. evansi found in camels in Kenya, Ethiopia and Sudan (Fikru et al., 2015). For parasite detection in
blood, the mini Anion Exchange Centrifugation Test (mAECT) can be used. The detection limit is
100 parasites/mL. The version that is used for human African trypanosomiasis is applicable to horse
and camel. For goat, a slight adaptation of the buffer is necessary (Guttierrez et al., 2004).
Control tools
Parameter 2 – Existence of control tools
Control tools are: (i) the use of trypanocidal drugs (which can never guarantee to get rid of the
parasites due to possible extravascular localisation of the parasites (Schillinger and R€ottcher, 1986), (ii)
isolation of infected animals under biting-ﬂy proof conditions, (iii) slaughtering of the infected animals,
(iv) destruction of carcasses is necessary as well as any issues from the infected animals since the
parasite can survive in fresh blood, meat and other organs possibly up to 2 days, and be a source of
infection for carnivores; (v) additional control of biting insects is necessary in the case of herbivores
(Desquesnes et al., 2013a).
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
The disease is currently not present at EU continental level; however, the Canary Islands
experienced Surra epidemics in camels (Tamarit et al., 2010).
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
In enzootic countries, important losses concern milk, meat, manure production, work capacity,
semen quality and reproduction performances (Enwezor and Sackey, 2005; Salah et al., 2015), including
treatment costs, intercurrent diseases, death and abortion (Silva et al., 1995a; Seidl et al., 1997). About
13% of the horses would be lost in the absence of control of Surra in the Pantanal, Brazil (Seidl et al.,
2001). In Philippines, the birth rate of buffaloes has been reported as 47% in non-infected females
compared to 15% in infected ones (Dargantes et al., 2009). In India, Surra is thought to be responsible
of very heavy loss, but there are no percentages of production loss available (Pathak and Singh, 2005).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Transmissibility between animals and humans
Parameter 1 – Types of routes of transmission between animals and humans
The rare cases of infections of humans by T. evansi have been reported to be either accidental
inoculation (iatrogenic) or contamination by infected meat or blood through a skin wound (Joshi et al.,
2005, 2006; Powar et al., 2006; Shegokar et al., 2006; Van Vinh Chau et al., 2016).
Parameter 2 – Incidence of zoonotic cases
The incidence of zoonotic cases is very low since fewer than 10 cases have been described so far
(Truc et al., 2013); most of the humans are not susceptible to the infection due to the presence of
trypanolytic factors (among which ApoL1 would be determinant) in normal human serum
(Vanhollebeke et al., 2006). However, in a recent case reported in Vietnam, the ApoL1 level and DNA
sequence appeared to be normal, thus, the development of T. evansi in this non-immunosuppressed
patient is not fully understood (Van Vinh Chau et al., 2016) and might have been due to transient
insufﬁciency in ApoL1.
Transmissibility between humans
Parameter 3 – Human to human transmission is sufﬁcient to sustain sporadic cases or community-level
outbreak
There is no information available, while the number of human cases is low.
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Parameter 4 – Sporadic, endemic, epidemic, or pandemic potential
The level of human cases is low, so primarily sporadic potential.
The severity of human forms of the disease
Parameter 5 – Disability-adjusted life year (DALY)
In the two recent fully documented cases (India and Vietnam), survival of the patient was a serious
concern due to high parasitaemia, and the disease appeared to be very similar to the rhodesiense
form of sleeping sickness in its blood phase (phase 1), thus, to avoid any risk of passage to phase 2
(neurologic invasion) the patients were treated using suramin. Due to the disease and convalescence,
these two patients were unable to work for several months.
The availability of effective prevention or medical treatment in humans
Parameter 6 – Availability of medical treatment and their effectiveness (therapeutic effect and any
resistance)
In the two recent fully documented cases (India and Vietnam), fully curative treatments were
obtained using suramin (1 g intravenous, 5 times at 1 week interval) (Joshi et al., 2006; Van Vinh
Chau et al., 2016).
Parameter 7 – Availability of vaccines and their effectiveness (reduced morbidity)
None are available due to the ability of Trypanosomes to exhibit a series of variable surface
glycoproteins. All attempts to develop vaccines were so far unsuccessful.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
The clinical expression of Surra generally includes fever, anaemia, loss of appetite and weight, loss
of condition and productivity, oedema, nervous signs and/or abortion, cachexia, and death, with or
without more peculiar signs related to the host species. However, the severity is variable from one
species to another.
The most severe clinical cases of Surra are observed in horses, dogs and camels and to a lesser
extent in donkeys and mules; treatment may be efﬁcient when applied early, otherwise the evolution is
most often fatal after recurrent fever, anaemia and loss of condition.
In horses, the course is most often acute, in later stages, invasion of the nervous system leads to
neurological signs. In endemic areas, such as India and Latin America, chronic forms are observed
however, the issue remains fatal most of the time (Gill, 1977; Jaiswal et al., 2015).
In camels, the course can be acute, subacute or chronic; in acute cases, clinical signs are
intermittent, in chronic form, the course of the disease is 1–3 years with clinical signs including
anaemia, emaciation, skin abscess and pica in young camels (Rottcher et al., 1987; Singh and Singla,
2013).
Dogs present very severe clinical signs, including, anaemia, bilateral keratitis and fatal evolution,
while the treatment is of low efﬁcacy (Rjeibi et al., 2015).
In buffaloes and cattle, the severity is mild in Africa and Latin America but high in recently infected
herds in Asia, with frequent abortion and a mortality reaching 20–90% (Gill, 1977). In cattle, fever,
abortion, and decreased milk production are frequently reported and high mortality can be recorded.
In all cases, if the clinical signs recede, it is suspected that Surra exacerbates other latent infections
and jointly very long impairments (Desquesnes et al., 2013b; Jaiswal et al., 2015). In sheep and goats,
the clinical signs are generally mild (Pathak and Singh, 2005; Jaiswal et al., 2015) but in acute
evolution sheep may die within 2 weeks accompanied by spleen and lymph nodes enlargement (Audu
et al., 1999). Pigs are generally symptomless or exhibit very mild signs with fever, anorexia, emaciation
and abortion (Arunasalam et al., 1995).
In domestic elephants, Surra has severe clinical signs, the animals are unable to work and the
disease may have potential fatal evolution; some animals may recover with or without treatment, and
may also become chronic (Evans, 1910).
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3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
• Asian elephants: Elephas maximus (endangered (IUCN, online); appendix 1, CITES)
• Asian rhinoceros: Dicerorhinus sumatrensis (critically endangered (IUCN, online); appendix 1,
CITES)
• Asiatic black bear: Ursus thibetanus (vulnerable (IUCN, online); appendix 1, CITES)
• Tayassuidae species (appendix 1 and 2, CITES)
• Vulpes bengalensis and Vulpes vulpes (appendix 3, CITES)
• Panthera tigris, Panthera. pardus, Panthera. onca, Leopardus pardalis (appendix 1, CITES)
• Pongo pygmaeus (appendix 1, CITES)
• https://www.cites.org/eng/app/appendices.php
Parameter 2 – Mortality in wild species
Surra can be fatal in rhinoceros, elephants, deer, wild pigs and carnivores, however, the morbidity
and mortality are unknown in these species. In Latin America, capybara seems to be affected, but a
part of the population is subclinical or healthy carrier (Morales et al., 1976).
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
T. evansi is not persisting in the environment. Wild carnivores may get the infection by eating a
prey of freshly killed infected animal (Jaiswal et al., 2015).
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
Surra is not on the list of the CFSPH for animal disease from potential bioterrorism agent and it is
on the OIE-Listed diseases, infections and infestations in force in 2017 (OIE, online)
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
It is not listed.
Parameter 3 – Included in any other list of potential bioagroterrorism agents
It is not listed in the CDC Bioterrorism Agents/Diseases.
https://emergency.cdc.gov/agent/agentlist.asp
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
The diagnostic methods recommended by the OIE (OIE, 2012) are listed in Section 3.1.1.8.
Two types of T. evansi are described. Type A is the most common. It is found in all countries where
T. evansi is endemic, and type B is rare and has been isolated from dromedary camels in Kenya and
Ethiopia (Ngaira et al., 2004, 2005; Njiru et al., 2006; Birhanu et al., 2015, 2016). Moreover, molecular
evidence exists that T. evansi type B also occurs in Sudan where almost half of the tested strains (13/30)
were of type B (Salim et al., 2011).
As concerns molecular diagnosis, the existence of non-RoTat parasites leaves room for false
negative results when using RoTat 1.2 speciﬁc primers in PCR diagnosis.
As concerns serological diagnosis, beside the presence of the RoTat 1.2 gene, which seems to be
predominant, it appears that the RoTat 1.2 VSG is not always expressed since a signiﬁcant part of
samples positive with RoTat1.2 PCR are negative by CATT, whose sensitivity may be as low as 72–80%
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in camels (Pathak et al., 1997; Fikru et al., 2015), 12% in cattle (Desquesnes et al., 2011) and
somehow inconsistent in pigs (Holland et al., 2005).
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Trypanosome infection evolves by waves of parasitaemia (ups and downs, in links with the
production of speciﬁc antibodies recognising a current variant surface glycoprotein (VSG)), which
generates inconsistent sensitivity of the parasitological and molecular techniques; for this reason,
iterating sampling of suspected animals improves the detection. Conversely, antibody levels are more
stable and antibody detection is more reliable, especially IgG detection (IgG levels are known to be
stable in the serum of infected animals), thus they provide better negative predictive value (NPV) than
parasitological and molecular techniques.
• Giemsa stained blood smear (GSBS): cheap and fast, the sensitivity of the test is very low; it can
be positive when the parasitaemia is > 105 parasites/mL; speciﬁcity of the test allows subgenus
identiﬁcation (Trypanozoon); cattle and small ruminants can be infected with non-pathogenic
trypanosomes, respectively, Trypanosoma theileri and Trypanosoma melophagium that are easily
distinguished from trypanozoons on morphological basis (length 60–120 lm, larger kinetoplast
(1–1.2 lm)); GSBS has a very high positive predictive value (PPV) but NPV is very low due to its
very low sensitivity.
• HCT: cheap and fast, sensitivity of the test is low; it can be positive when the parasitaemia is
> 102–3 parasites/mL.
• Mouse inoculation technique (MIT): it is time consuming and presents ethical concerns (using
live animals), however, sensitivity of the test is high; it can be positive when the parasitaemia
is > 10 parasites/mL; speciﬁcity allows subgenus identiﬁcation through GSBS and molecular
characterisation after multiplication in mice; MIT allows parasite isolation for further
characterisation; PPV is very high but NPV is low.
• PCR: medium cost and delayed, but sensitivity is high; it can be positive when the
parasitaemia is > 1–100 parasites/mL (depending on the PCR and DNA preparation methods
used); it allows parasite characterisation at various levels: subgenus, species and type; PPV is
very high (only contamination in PCR would lead to false positive result) but NPV remains low
in case of low parasitaemia.
• The speciﬁcity of the PCR test with TBR primers is jeopardised by its extremely high sensitivity,
thus making it prone to contamination which may affect its PPV.
• mAECT: medium cost. Not widely available and only applicable on camel, horse and goat. Very
high speciﬁcity and high sensitivity (< 100 trypanosomes/mL).
• CATT: cheap and fast, sensitivity is generally high in Equidae, buffalo, camels, sheep, goats
and dogs, with a medium to high speciﬁcity; speciﬁcity and sensitivity are low in cattle high
PPV and medium NPV in horses, dogs and camels; lower values in other host species.
• Antibody ELISA: cheap but delayed; the sensitivity and speciﬁcity are high (90–95% on
average) in horses, camels, bovines and buffaloes; positive seroconversion is around 2 weeks
while negative seroconversion is around 3–4 months; PPV is high providing treatment are
documented; NPV very high unless very recent infection.
• Trypanolysis test (TL): very expensive and delayed, TL is used for conﬁrmation of CATT or
ELISA positive cases. The sensitivity is considered as high. The speciﬁcity is very high and even
strain dependent; indeed, only strains expressing RoTat 1.2 gene can be positive; most of the
T. evansi strains from the whole distribution area of T. evansi are type A, thus considered to
express RoTat 1.2 as an early antigen; however, some rare strains deﬁned as type B, such as
described in Kenya, Ethiopia and Sudan, cannot be detected using TL.
Antibody detection tests remain positive several months after curative treatment and therefore for
assessment of treatment success they are only appropriate under medium term follow-ups (3–6 months).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
• Blood from large veins
• Blood from capillary vessels (sensitivity might be better for parasitological examinations)
• Oedema liquid
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• Lymph node liquid
• Cerebrospinal ﬂuid (CSF)
• Genital ﬂuid (vaginal or preputial ﬂush)
• Impression smears of lungs, liver, and kidney can be made at post-mortem (OIE, online).
3.1.4.2. Article 7(d)(ii) Vaccination
No vaccines are available.
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
• Diminazene aceturate (DA) is an aromatic diamidine used to control Babesia and trypanosome
infection in ruminants (bovines, sheep, goats); it can be used in equines and dogs but
exhibiting poor efﬁcacy and tolerance in these species. The dose recommended for the
treatment of infections due to parasites belonging to the Trypanozoon subgenus is 7 mg/kg
body weight (bw) of DA, via intramuscular injection.
• Isometamidium chloride (ISMC) belongs to the phenanthridine family but it is not known as a
carcinogenic agent; it can be used for curative (0.5 mg/kg bw) and preventive (1 mg/kg bw)
treatment of trypanosome infections in ruminants, camels, horses and dogs via intramuscular
or subcutaneous injection. Horses have a limited tolerance to ISMC (Toro et al., 1983),
although it remains an alternative to DA.
Note: Homidium and ethidium also belong to the phenanthridine family; they have been used
in the past, especially in East Africa, however, they are highly toxic because they are DNA
intercalating agents; their mutagenic action was demonstrated early (McCann et al., 1975).
Therefore, their use in the ﬁeld is not recommended.
• Quinapyramine (QP) belongs to the group of aminoquinaldine derivatives. Quinapyramine
methyl-sulfate can be used to cure infection by subcutaneous injection at a dose of 5 mg/kg
bw. A more effective combination of quinapyramine sulfate and quinapyramine chloride
(Triquin) can be used as a curative/preventive drug against T. evansi in horses and camels
(4 months protection).
• Melarsomine hydrochloride (MH) is used to control Surra in camels via deep intramuscular
injection at a dose rate of 0.25 mg/kg bw. Evaluations conducted on other host species
suggest using rates of 0.25–0.5 mg/kg bw in horses, 0.5 mg/kg bw in cattle, and 0.75 mg/kg
bw in buffaloes (Lun et al., 1991; Payne et al., 1994; Desquesnes et al., 2011). Dogs have a
satisfactory tolerance to the drug, up to 1–2 mg/kg bw.
Parameter 2 – Availability/production capacity (per year)
None of these drugs are available on the French market; however, some of these products are
produced in France (DA, ISMC and MH), and the production capacities are high for exportation mostly
to Africa. Other countries such as India, China and Brazil are also producing some of these drugs (DA,
ISMC and QP). In total, 40 million of doses of trypanocides are sold every year only in Africa (Akoda
and Peter, 2015). Some of the drugs available at markets, in particular in Africa, are however very
often of poor quality, counterfeit or fake (Tchamdja et al., 2016) and it is wise to ascertain the origin
of trypanocidal drugs to be used successfully (Sutcliffe et al., 2014).
Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
• DA: If the objective of a treatment is to cure the animal and get rid of the infection, high
doses such as 7–10 mg/kg bw should be used; however, success cannot be ascertained and
toxicity may limit such practice. Although recommended at the dose of 7 mg/kg bw for
Trypanozoon infections, the reality in the ﬁeld often reveals that a dose of 3.5 mg/kg bw is
used to control Surra. This could be for various reasons, including ignorance of the right dose,
fear for side effects or to induce a shock using high dose, or concern to save money by
reducing the cost of treatment. On the other hand, DA has been used for a very long time.
Consequently, trypanosomes have developed chemoresistance in most parts of the world
(Peregrine and Mamman, 1993). Using 3.5 mg/kg bw to control T. evansi can be considered as
AHL assessment on Trypanosoma evansi infections (including Surra)
www.efsa.europa.eu/efsajournal 15 EFSA Journal 2017;15(7):4892
underdose, as is often the case, and thus it can help to cure clinical affection, but most of the
time the animals will remain carriers of the parasites (Desquesnes et al., 2013a). Finally, in dog
treatment, in order to avoid toxic effects but to increase the drug efﬁcacy, serial treatments
using 3.5 mg/kg have been attempted (Howes et al., 2011).
• ISMC: If the objective is to cure the animal and get rid of the infection, high doses such as
1–2 mg/kg bw should be used; however, success cannot be ascertained and toxicity may limit
such practice. In addition, as a slow eliminated drug, ISMC may easily induce resistance, so it
is not a drug of choice for the control of Surra. The withdrawal period for the consumption
for cattle injected with IMC is 23 days; which makes IMC poorly adaptable to beef or dairy
cattle. Alternate use of DA and ISMC constitutes a ‘sanative pair’, which means that once
resistance develops to one of the drugs, the other drug should be used to control the
infection (Dia and Desquesnes, 2004).
• QP is very efﬁcient in horses and can both cure and prevent infection for several months (Dia
and Desquesnes, 2004; Desquesnes et al., 2013a). In cattle, the use of QP is not
recommended because it may induce cross-resistance to both DA and IMC (Peregrine et al.,
1995). Its use should be restricted to horses and camels only at a dose of 5 mg/kg bw.
• MH is used to control Surra in camels, however, some resistance is already suspected. A dose
of 0.5 mg/kg bw can be used in camels and horses, while higher doses may be required for
successful treatment in bovines.
To date, treatments for bovines in the ﬁeld are for clinical improvement; it is rare that farmers and
veterinarians attempt to get rid of the infection in these hosts.
Conversely, in horses and camels, cure and prevention are necessary and may be obtained using
high doses of MH and QP, but only in the blood stage of the infection, since none of these drugs can
reach and kill the parasite once the nervous system is invaded.
Feasibility
Parameter 4 – Way of administration
DA and ISMC should be administered via deep intramuscular injection to obtain a high
concentration of the chemical in the circulating blood, and to avoid irritant and local reactions.
QP and MH can be administered intramuscularly or by subcutaneous route.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
There are no current rules since the disease is not present in the EU, so these are suggestions
based on the current knowledge of the disease and past experiences.
External biosecurity measures should focus on controlling the introduction of certainly non-infected
livestock (see diagnosis method under point 3 below), and internal biosecurity measures should focus
on separating infected from uninfected animals, administration of curative trypanocidal drugs or
slaughtering of infected animals, close follow-up of exposed animals and controlling biting ﬂies using
protections (mosquito nets) and insecticide treatments (spray).
Care should be taken while slaughtering infected animals and to keep all issues from dead or
slaughtered animals for a minimum of 3 days. Destruction of the carcasses and all issues is
recommended.
Example of monitoring of a case or an outbreak:
The following measures were successfully applied more than a century ago in a historical case of
introduction of Surra infected cattle from India to the USA (Mohler and Thompson, 1909):
1) Isolation of infected and exposed animals under individual ﬂy-proof stables;
2) Detection of infection amongst the exposed animals by all diagnostic methods available
[parasitological, molecular and serological methods should be used nowadays] including rabbit
(as was done in the USA) or mouse inoculation technique, three times at 1 month interval;
3) Killing of infected animals;
4) Follow-up of remaining animals for detection of infection using parasitological, molecular
and serological techniques for another 9 months.
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Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
Preventing pathogen introduction into the EU predominantly means preventing the introduction of
infected animals, especially herbivores (because the infection is most often fatal to the carnivores and
they are a poor source of infection, mostly considered as an epidemiological cul-de-sac).
For camelids that are introduced to the EU and originating from non-authorised countries, a
quarantine must be made in Saint Pierre et Miquelon, and certiﬁcates must be provided (RUM and
CAM); however, the laboratory tests are of poor efﬁciency since only negative blood smear
examination 2 and more than 42 days after their arrival is requested (Annex I to Regulation (EC)
No 206/2010); this diagnosis method being of a very low sensitivity, the risk of undetected carrier is
signiﬁcant. Moreover, these measures should be extended to any infected part of a country such as
the Canary Islands, where it is endemic and has been source of infection for the mainland of Spain
and France.
Alternatively, the infection might be introduced into the EU via uncontrolled or wild animals,
through geographical continuity, especially from Turkey through Greece or Bulgaria. Animal movements
between these countries might not be fully under control.
Feasibility
Parameter 3 – Feasibility of biosecurity measures
A series of measures to prevent and control Surra in the EU have been proposed to the OIE (not
yet approved), as indicated hereafter.
Recommendations for the trading of equines and camelids:
Two quarantines should be applied for international trading of equines and camelids from a country
infected to a non-infected country: a quarantine of 4 weeks in the exporting farm and a quarantine of
4 weeks in the importing farm.
To be allowed for trading an animal should originate from a non-infected farm in a non-suspect
area, and be negative to Surra tests twice at 3–4 weeks interval during each of the quarantines.
A farm is in a non-suspect area if, in the surrounding of 30 km from its limits, there has been no
report of Surra in the last 3 years.
A non-infected farm is a farm located in a non-suspect area, which allows only the introduction of
animals negative to Surra tests (according to OIE), originating from a non-infected farm in a non-
suspect area. To get the status of a non-infected farm, all mammal animal species must be proved
negative to Surra tests twice at 3 months interval. To keep this status, all domestic mammal animal
species should prove to be negative to Surra tests after every 10–12 months.
Isolation measures:
Feasibility of isolation, detection and killing was satisfying in the USA experience in 1906 (Mohler
and Thompson, 1909).
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
There are no current restrictions since the disease does not exist in the EU at the present time, but as
was done in the case of the two outbreaks observed in Spain and France, animal movements were
forbidden as soon as a case or outbreak was identiﬁed. Since Surra is a multispecies disease, restriction of
all mammal animal movements should be applied until the farm can be declared as non-infected by Surra.
For horses that fall in the category of HHP (sport, breeding, exhibition), OIE is currently
establishing particular regulations that are less strict in terms of quarantine depending on the low-risk
environment in which these horses are kept.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
There are no current rules since the disease is not present in the EU; however, the restrictions
applied in the cases of these outbreaks concerned animals and products (milk, blood, meat and any
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carcass issues); these restrictions have been efﬁcient since the disease did not spread outside the
infected farms.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
Because Surra is a multispecies disease and because diagnosis at the individual level is inaccurate due
to latent infection, restriction of animal movement should be applied at the farm level to all mammals.
Restriction of animal movement is feasible; however, rules should be elaborated and prescribed, even in
the absence of the disease, so that they may be applicable as soon as the disease is identiﬁed in the EU.
Restriction of movements of wildlife would also be ideal although uncertain; in this case, deer,
rabbits, hare, wild pigs and rodents, foxes, wolves, feral dogs and cats might be concerned; feasibility
of their movement restriction is uncertain (information based on the French experience and expert
opinion).
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
Animal killing measures are not applied in the EU due to Surra since the disease is not present.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
Unless all animals have been individually isolated under ﬂy-proof conditions, effectiveness of killing
infected animals within the farm may be low due to latent infections and potential false negative
results to all diagnostic methods, thus, long-term follow-up is requested (12 months) to ensure
complete effectiveness.
Farm level killing is safer but might not be justiﬁed, depending on the conditions of the outbreak. If
successfully applied, the measure would be fully efﬁcient.
Killing of animals was effective in two historical examples: (1) in Australia, where Surra was found
once in imported camels at Port Hedland in 1907 (Hoare, 1972), and (2) in the USA, where Surra was
introduced into three cattle imported from India in 1906; in the latter case, the strict isolation of the
animals in ﬂy-proof conditions, diagnosis through rabbit inoculation and killing of infected animals led
to successful eradication (Mohler and Thompson, 1909).
Feasibility
Parameter 3 – Feasibility of killing animals
Killing of ruminants might be accepted by farmers, due to other pre-existing rules for other
diseases in these stocks; however, for horses and camels, farmers are more reluctant to slaughter,
which may lead to a low immediate feasibility. This was observed in the outbreak in camels in the
Aveyron, France (Desquesnes et al., 2008), where, despite the Ministerial decision for the culling of
infected/positive animals, the measures were not applied due to legal claims by the camel’s owner.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Because Surra is sporadic in the EU, a limited number of animals would be concerned, so
destruction of the carcasses and all associated material is recommended. However, if high value or
high numbers of animals are concerned, economic parameters might lead to meat from animals
slaughtered due to Surra infection being used; based on expert knowledge, care must be taken as
concerns slaughtering since the blood and other issues are contagious; after 1 week maturation at 4°C
or below, meat would be safe for animal and human consumption. Milk products should be heat
treated to inactivate the parasite.
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Effectiveness
Parameter 2 – Effectiveness of disposal option
Survival of T. evansi in blood and meat is estimated to 2 days, thus, 1 week maturation at 4°C
would be safe for animal and human consumption; however, care must be taken as concerns
slaughtering conditions since the blood and other issues are contaminative. Survival of T. evansi in milk
has not been determined but could also range around 2 days, thus, milk should not be used raw
because peroral infection through milk is possible (Campigotto et al., 2015). Milk products should be
heat treated to kill the parasites.
Feasibility
Parameter 3 – Feasibility of disposal option
Speciﬁcally equipped slaughterhouses and well-trained technicians might operate the culling for
appropriate disposal options. All other issues should be destroyed to avoid human exposure and
spreading through wild rats and roaming dogs and cats.
A risk might remain for carnivores such as dogs and cats to get contaminated in the farm through
eating raw milk (Campigotto et al., 2015), placenta or carcass of infected animals.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
There has been no ofﬁcial assessment of this aspect.
Parameter 2 – Cost of eradication (culling, compensation)
Cost of culling in ruminants would not be different from other diseases and might concern either
positive animals through a 1 year follow-up or all animals on the farm.
Parameter 3 – Cost of surveillance and monitoring
Although studies assessing the costs for surveillance for Surra are not available, the following could
be supposed:
• If the current four diagnosis methods recommended by the OIE are applied, cost of
surveillance and monitoring can be estimated at around 80–100 €/sample. Since animals
should be checked with the 4 tests every month for 12 months, a laboratory cost of around
1,200 €/head can be predicted;
• A TL can be performed to conﬁrm CATT and ELISA, however the TL is time consuming and the
cost, around 250 €/sample, would increase the total cost of such follow-up by 9 3.5 (OIE, 2012).
Parameter 4 - Trade loss (bans, embargoes, sanctions) by animal product
These might be signiﬁcant in camels and horse farm activities, as well as in milk and/or meat
producing farms for animal product trading, but this has not been assessed formally.
Parameter 5 - Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector
There has been no assessment of this aspect.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
So far, there have been two recent outbreaks of Surra in Europe: in France and Spain.
Killing of horses and camels generally can be considered with low societal acceptance.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Animal welfare can be affected if offspring is isolated from their dam at birth, which is recommended
due to a possible passage of the parasite through milk and colostrum (Campigotto et al., 2015).
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Parameter 2 – Wildlife depopulation as control measure
No impact on the environment and biodiversity has been identiﬁed, and wild rodents have not been
identiﬁed as an active source of infection so far (Rodrıguez et al., 2010).
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
When vector control is attempted using insecticide sprays, insecticide residues can be spread in the
environment, and then contaminate soil, water, feed and manure. However, such contamination would
not be greater than those generated by any other insecticide/acaricide treatment which could be
applied for the control of ticks or biting ﬂies.
There are no data on the potential residuals of trypanocidal drugs in environmental compartments.
Biodiversity
Parameter 2 – Mortality in wild species
No impact on the environment and biodiversity has been identiﬁed, but if wildlife is implicated in
transmission (deer, wild pigs, etc.), and regulation of wildlife is deemed needed, a systematic
assessment of the biodiversity would be required.
In Latin America, capybara control might be of concern.
3.2. Assessment according to Article 5 criteria
This section presents, the results of the expert judgement on the criteria of Article 5 of the AHL
about T. evansi infections (including Surra) (Table 1). The expert judgement was based on Individual
and Collective Behavioural Aggregation (ICBA) approach described in detail in the opinion on the
methodology (EFSA AHAW Panel, 2017). Experts have been provided with information of the disease
fact-sheet mapped into Article 5 criteria (see supporting information, Annex A), based on that the
experts indicate their Y/N or ‘na’ judgement on each criterion of Article 5, and the reasoning
supporting their judgement.
The minimum number of judges in the judgement was nine. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 1: Outcome of the expert judgement on the Article 5 criteria for Trypanosoma evansi
infections (including Surra)
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following
criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
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3.2.1. Non-consensus questions
This section displays, the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 2, 3 and 4). The proportion of Y, N or na answers are reported,
followed by the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes:
• The measures taken to prevent introduction to EU appear to be effective, as evidenced by
occurrence of only very few sporadic outbreaks in the EU.
Supporting No:
• If the disease is introduced and spread, risk-mitigating measures may not be sufﬁcient. Even though
diagnostic tools are in place, they are not accurate for detection of latent infections. Furthermore,
vaccines are not available and chemotherapeutic treatment is not authorised in the EU.
• EU regulations and movement restriction are in place, except in some cases for Equidae (the
importation of potentially exposed/infected Equidae into Europe may occur) and camelids
(Canary Islands, Spain), which may pose a risk of introduction. There are similar concerns with
respect to the movement of animals from Turkey to Greece or Bulgaria.
Reasoning supporting the judgement
Supporting Yes:
• The disease could generate concern in the high-value horse and camel industries.
Supporting No:
• The disease is not listed as a bioterrorism agent.
Table 2: Outcome of the expert judgement related to criterion 5 A(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
A(v) Risk-mitigating measures and, where relevant,
surveillance of the disease are effective and
proportionate to the risks posed by the disease
in the Union
NC 78 22 0
NC: non-consensus; number of judges: 9.
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
Y
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
NC
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 3: Outcome of the expert judgement related to criterion 5 B(iv)
Question Final outcome
Response
Y (%) N (%) na (%)
B(iv) The disease has the potential to generate
a crisis or the disease agent could be used
for the purpose of bioterrorism
NC 44 56 0
NC: non-consensus; number of judges: 9.
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Reasoning supporting the judgement
Supporting Yes:
• The host range is very wide, and it is possible that endangered European species could be
affected.
• The disease can affect deer and carnivores, with potential high mortality, although data are
not available.
Supporting No:
• The population decrease in wildlife caused by the disease is unlikely to be signiﬁcant.
3.2.2. Outcome of the assessment of Trypanosoma evansi infections (including
Surra) according to criteria of Article 5(3) of the AHL on its eligibility to
be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 1, T. evansi
infections complies with criteria from A(i) to A(iv) of the ﬁrst set and the assessment is inconclusive on
compliance with criterion A(v). Therefore, it is inconclusive whether T. evansi infections can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about T. evansi infections (including Surra) (Tables 5, 6, 7, 8 and 9).
The expert judgement was based on ICBA approach described in detail in the opinion on the
methodology. Experts have been provided with information of the disease fact-sheet mapped into Article
9 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’
judgement on each criterion of Article 9, and the reasoning supporting their judgement. The minimum
number of judges in the judgement was nine. The expert judgement was conducted as described in the
methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of the questions see
Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 4: Outcome of the expert judgement related to criterion 5 B(v)
Question Final outcome
Response
Y (%) N (%) na (%)
B(v) The disease has or could have a signiﬁcant
negative impact on the environment,
including biodiversity, of the Union
NC 22 78 0
NC: non-consensus; Number of judges: 9.
Table 5: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for Trypanosoma evansi infections (Surra)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory of
the Union
Y
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y
AHL assessment on Trypanosoma evansi infections (including Surra)
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(7):4892
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, including
epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial costs,
mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets NC
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers of
animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the disease
OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to those
species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 6: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for Trypanosoma evansi infections (Surra)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free of
the disease
N
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
NC
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 7: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for Trypanosoma evansi infections (Surra)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
1 The disease is present in the whole OR part of the Union territory
with an endemic character
N
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
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3.3.1. Non-consensus questions
This section displays, the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 10, 11
and 12). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different
supporting views for each answer.
Table 8: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for Trypanosoma evansi infections (Surra)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
Criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 9: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for Trypanosoma evansi infections (Surra)
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply.)
NC
Colour code: yellow = no consensus (NC).
2.4 The disease usually does not result in high morbidity and has negligible or no mortality AND often
the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or possible
signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related to its
direct impact on certain types of animal production systems
N
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets NC
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers of
animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the disease
OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to those
species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 10: Outcome of the expert judgement related to criterion 4 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
4 (cat.A,B) The disease has a signiﬁcant impact on the
economy of the Union, causing substantial costs,
mainly related to its direct impact on the health
and productivity of animals
NC 89 11 0
NC: non-consensus; number of judges: 9.
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Reasoning supporting the judgement
Supporting Yes:
• Multiple animal species can be affected.
• If Surra is introduced into the EU, the impact may be signiﬁcant (high mortality and morbidity
described in horses and dogs).
Supporting No:
• There is currently no disease and therefore no impact within the EU, but if the disease was
introduced into the EU and no control was in place, the impact would be signiﬁcant.
Reasoning supporting the judgement
Supporting Yes:
• In endemic countries, although Surra has a very low prevalence (in very limited part of the EU
it can be endemic/epidemic, e.g. in Canary Islands), high mortality and morbidity has been
described in horses and dogs.
• The impact on society may be signiﬁcant because of the type of animals affected (companion
animals and valuable horses and camelids).
Supporting No:
• Currently, there is no impact on society or labour markets, since the disease is absent. If the
disease was introduced into the EU and no control was in place, the impact would be
signiﬁcant.
Reasoning supporting the judgement
Supporting Yes:
• Potential mortality in wild animals species at EU level including endangered species such as
carnivores (e.g. bear, lynx).
Supporting No:
• It may have potential mortality in wild animals species at EU level, but in general low
prevalence is recorded apart from endemic areas.
Table 12: Outcome of the expert judgement related to criterion 5(d) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(d) The disease has a signiﬁcant impact on a long-term
effect on biodiversity or the protection of endangered
species or breeds, including the possible disappearance
or long-term damage to those species or breeds
NC 11 89 0
NC: non-consensus; number of judges: 9.
Table 11: Outcome of the expert judgement related to criterion 5(a) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(a) The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
NC 33 67 0
NC: non-consensus; number of judges: 9.
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3.3.2. Outcome of the assessment of criteria in Annex IV for
Trypanosoma evansi infections (including Surra) for the purpose of
categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 3–7. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for Trypanosoma evansi
infections (including Surra) for the purpose of categorisation as in Article 9 of the AHL is presented in
Table 13.
According to the assessment here performed, Trypanosoma evansi infections (including Surra)
comply with the following criteria of the sections 1–5 of Annex IV of the AHL for the application of the
disease prevention and control rules referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment T. evansi infections comply with criteria 1,
2.2, 2.3 and 2.4 but not with 2.1. To be eligible for category A, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and T. evansi infections
comply with criterion 5b, do not comply with criteria 3 and 5c and the assessment is
inconclusive on compliance with criteria 4, 5a and 5d.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment T. evansi infections comply with criteria 2.1,
2.2 and 2.3 but not with 1 and 2.4. To be eligible for category B, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and T. evansi infections
comply with criterion 5b, do not comply with criteria 3 and 5c and the assessment is
inconclusive on compliance with criteria 4, 5a and 5d.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment T. evansi infections comply with criteria 2.1,
2.2 and 2.3 but not with 1 and 2.4. To be eligible for category C, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and T. evansi infections
comply with criterion 5b, do not comply with criteria 3, 4 and 5c and the assessment is
inconclusive on compliance with criteria 5a and 5d.
Table 13: Outcome of the assessment of criteria in Annex IV for Trypanosoma evansi infections
(including Surra) for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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4) To be assigned to category D, a disease needs to comply with criteria of section 1, 2, 3 or 5 of
Annex IV of the AHL, whose assessment performed is inconclusive for T. evansi infections, and
with the speciﬁc criterion D of section 4, which T. evansi infections comply with.
5) To be assigned to category E, a disease needs to comply with criteria of section 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5 and the assessment here
performed for T. evansi infections is inconclusive on compliance with the criteria as in Article 5.
3.4. Assessment of Article 8
This section presents, the results of the assessment on the criteria of Article 8(3) of the AHL about
T. evansi infections (including Surra). The Article 8(3) criteria are about animal species to be listed, as
it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.3 According to the
mapping, as presented in Table 5, section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for T. evansi infections (including
Surra) according to the criteria of Article 8(3) of the AHL are as displayed in Table 14.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, it is inconclusive whether T. evansi infections
(including Surra) can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL. Eligibility of listing T. evansi infections (including Surra) is dependent
on a decision on criterion 5 A(v).
Table 14: Animal species to be listed for Trypanosoma evansi infections (including Surra) according
to criteria of Article 8 (source: data reported in Section 3.1.1.1 and 3.1.1.6)
Class Order Family Genus/species
Susceptible Mammalia Almost all Almost all Almost all
Reservoir Mammalia Artiodactyla Bovidae Almost all
Cervidae Not speciﬁed
Suidae Sus scrofa
Camelidae Not speciﬁed
Perissodactyla Equidae Equus spp.
Rodentia Caviidae Hydrochoerus hydrochaeris
Chiroptera Phyllostomidae Desmodus rotundus,
Diphylla ecaudata, Diaemus youngi
Vectors Insecta Diptera Tabanidae Tabanus spp., Chrysops spp.,
Haematopota spp.
3 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, since it is inconclusive whether T. evansi
infections (including Surra) can be considered eligible to be listed for Union intervention as laid
down in Article 5(3) of the AHL, then also the assessment of its compliance with the criteria as
in Sections 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and
control rules referred to in points (d) and (e) of Article 9(1) of the AHL is inconclusive.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, since it is inconclusive whether T. evansi infections
(including Surra) can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL, then it is also inconclusive which animal species can be considered to be
listed for T. evansi infections (including Surra) according to Article 8(3) of the AHL.
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Abbreviations
AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
ApoL1 apolipoprotein-L1
bw body weight
CATT card agglutination trypanosomiasis test
CFSPH Center for Food Security and Public Health
CITES The Convention on International Trade in Endangered Species of Wild Fauna and Flora
CSF cerebrospinal ﬂuid
DA diminazene aceturate
DALY disability-adjusted life year
ELISA enzyme-linked immunosorbent assay
FAO Food and Agriculture Organization of the United Nations
GSBS Giemsa stained blood smear
HCT haematocrit centrifuge technique
HHP high health, high performance
ICBA Individual and Collective Behavioural Aggregation
IgG immunoglobulin G
ISMC isometamidium chloride
IUCN International Union for Conservation of Nature
mAECT mini Anion Exchange Centrifugation Test
MH melarsomine hydrochloride
MIT mouse inoculation technique
MS Member State
NPV negative predictive value
OIE World Organisation for Animal Health
PCR polymerase chain reaction
PPV positive predictive value
QP quinapyramine
Se diagnostic sensitivity
Sp diagnostic speciﬁcity
TL trypanolysis test
ToR Terms of Reference
VSG variant surface glycoprotein
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